The development of oncogene-directed targeted therapies represents a new paradigm in the treatment of non-small cell lung cancer (NSCLC), offering improved outcomes compared with chemotherapy. Rearrangements of the anaplastic lymphoma kinase (ALK) gene are major oncogenic drivers in a subset of NSCLC patients. Since its launch in 2011, the ALK inhibitor crizotinib has become the standard of care in ALK-positive NSCLC, but resistance inevitably develops. Ceritinib and alectinib have received regulatory approval: the former in Europe, US and elsewhere in the world, the latter in Japan. ALK inhibitors target multiple pathways, and may therefore be associated with a wide range of adverse events (AEs), including gastrointestinal AEs, hepatotoxicity and, in the case of crizotinib and ceritinib, cardiac effects. While the majority of these AEs are reversible, manageable and not severe, it is important that both physician and patients are aware of toxicities to ensure prompt treatment. This article discusses the management of AEs in patients receiving currently approved ALK inhibitors, including treatment, regular monitoring, drug discontinuation or dose reduction and physician/patient education. Proactive management of AEs enhances patient quality of life and optimises the therapeutic index of these agents.
Alectinib, ceritinib, crizotinib, ALK-positive non-small cell lung cancer
Christian Rolfo has served on the Novartis International Speakers Bureau. Solange Peters and Ignacio Gil-Bazo have no conflicts of interest to declare.
Christian Rolfo, Associate Professor, University Hospital Antwerp Oncology, Head of Phase I Early Clinical Trials Unit, Antwerp, Belgium. E: [email protected]
The publication of this article was supported by Novartis, who were given the opportunity to review the article for scientific accuracy before submission. Any resulting changes were made at the author’s discretion.
This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
Related Content In Lung Cancer
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]
ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases
European Oncology & Haematology. 2020;16(1):18-21 DOI: https://doi.org/10.17925/EOH.2020.16.1.18
At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in all comers.1 The presence of CNS disease is an indicator of poor prognosis in […]
Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study
European Oncology & Haematology. 2019;15(2):86–8
Non-small cell lung cancer (NSCLC) remains a world-wide health issue, accounting for 85% of all lung cancers, of which there were an estimated 2.1 million new cases and 1.76 million deaths in 2018; equivalent to 11.6% of the global cancer burden.1,2 This incidence is expected to rise in the coming years as rates of smoking increase […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!